Currently, there is no consensus on the optimal management of patients with multifocal, HP-negative, or persistent disease after HP eradication.[4] In this report, we describe a case of MALT lymphoma with API2/MALT refractory to HP eradication therapy. Here, BIRC3 is linked to MALT lymphoma.